- Home
- SRRK vs DXC Comparison
SRRK vs DXC Comparison
Compare SRRK & DXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRRK
- DXC
- Stock Information
- Founded
- SRRK 2012
- DXC 1959
- Country
- SRRK United States
- DXC United States
- Employees
- SRRK N/A
- DXC N/A
- Industry
- SRRK Biotechnology: Biological Products (No Diagnostic Substances)
- DXC EDP Services
- Sector
- SRRK Health Care
- DXC Technology
- Exchange
- SRRK Nasdaq
- DXC Nasdaq
- Market Cap
- SRRK 4.2B
- DXC 3.6B
- IPO Year
- SRRK 2018
- DXC N/A
- Fundamental
- Price
- SRRK $43.07
- DXC $21.58
- Analyst Decision
- SRRK Strong Buy
- DXC Hold
- Analyst Count
- SRRK 7
- DXC 9
- Target Price
- SRRK $40.43
- DXC $20.89
- AVG Volume (30 Days)
- SRRK 1.2M
- DXC 929.8K
- Earning Date
- SRRK 11-12-2024
- DXC 01-30-2025
- Dividend Yield
- SRRK N/A
- DXC N/A
- EPS Growth
- SRRK N/A
- DXC N/A
- EPS
- SRRK N/A
- DXC 0.13
- Revenue
- SRRK N/A
- DXC $13,262,000,000.00
- Revenue This Year
- SRRK N/A
- DXC N/A
- Revenue Next Year
- SRRK N/A
- DXC N/A
- P/E Ratio
- SRRK N/A
- DXC $167.01
- Revenue Growth
- SRRK N/A
- DXC N/A
- 52 Week Low
- SRRK $6.76
- DXC $14.79
- 52 Week High
- SRRK $46.19
- DXC $25.09
- Technical
- Relative Strength Index (RSI)
- SRRK 69.26
- DXC 48.17
- Support Level
- SRRK $40.95
- DXC $21.13
- Resistance Level
- SRRK $44.22
- DXC $22.90
- Average True Range (ATR)
- SRRK 2.57
- DXC 0.56
- MACD
- SRRK -0.12
- DXC -0.14
- Stochastic Oscillator
- SRRK 73.14
- DXC 21.47
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGFβ1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.
About DXC DXC Technology Company
DXC Technology Co is a vendor-independent IT services provider. The company's operating segment includes Global Business Services (GBS) and Global Infrastructure Services (GIS). It generates maximum revenue from the GIS segment. GIS offerings include Cloud and Security; IT Outsourcing and Modern Workplace. Geographically, it derives a majority of revenue from the Other Europe region.